Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammation and Neurological Disease Development.
Key Molecular Features
- Functional Domain: PDEase (UniProt P27815)
- Key Mutations: rs1051738 (dbSNP), rs2230190 (dbSNP)
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PDE4A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Enzyme | PDE4A Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified Active Enzyme. |
View PDE4A Products |
| Gene Delivery | PDE4A Promise-ORF / Lentivirus Full-length ORF for stable cell lines and cellular assays. |
View PDE4A Products |
| Benchmark Control | Anti-PDE4A Benchmark Antibody Recombinant positive control for assay validation. |
View PDE4A Products |
| Validator | PDE4A siRNA Set For knockdown verification and off-target screening. |
View PDE4A Products |
| Related Target A | PDE4D Critical for counter-screening to avoid emetic side effects. |
View PDE4D Products |
| Related Target B | PDE4B Key ortholog for comprehensive isoform selectivity profiling. |
View PDE4B Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (PDE4A vs PDE4D) | Homolog panel proteins (PDE4A, B, C, D) strictly verified by mass spec and sequence analysis |
| Enzymatic Assay Stability | High Purity (>95%) recombinant enzymes with Endotoxin Controlled environments |
| Lack of Reliable Controls | Benchmark Antibodies included for standardized immunoblotting and assay calibration |
| Cell-Based Target Validation | Validated siRNA included for specificity checks and pathway knockdown |
Live PDE4A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PDE4A therapeutics is intensifying, with major players shifting focus from traditional non-selective small molecules to targeted protein degraders (PROTACs) and highly selective allosteric inhibitors. As first-generation pan-PDE4 therapies proved clinically effective but hindered by gastrointestinal side effects (largely driven by PDE4D), the next wave of R&D is targeting precise PDE4A isoform selectivity to unlock therapeutic potential in neuroinflammation, respiratory diseases, and dermatology. The PDEase domain (UniProt P27815) is the catalytic core; mutations such as rs1051738 and rs2230190 are being investigated for their impact on inhibitor binding and patient stratification.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTACs / Degraders | Arvinas, Kymera | Inflammatory Diseases | Ternary Complex Validation (Need high-purity recombinant PDE4A) |
| Small Molecules | Amgen, Pfizer | COPD, Psoriasis | Selectivity Assay (Need Homolog Panels: PDE4A vs PDE4D) |
| Allosteric Inhibitors | Emerging Biotech | Neuroinflammation | Enzymatic Activity Assays (Need structurally intact active enzymes) |